The International Society for Pharmaceutical Engineering (ISPE) has recognized Eli Lilly Kinsale Limited as the Overall ...

As an investor in Eli Lilly stock, I'm encouraged by the company's forward thinking. Not only is management making moves to ...

Eli Lilly’s shares have surged 750 per cent over five years. Novo Nordisk’s are up about 360 per cent in the same period.

Eli Lilly’s senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.

In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company in the world.

All of this means Lilly investors shouldn't panic. Even in the "worst case," Lilly's weight loss drugs have driven major revenue growth, and this is likely to continue -- whether compounders halt ...

How Eli Lilly’s Next 5 Years Could Play Out We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

has recognized Eli Lilly Kinsale Limited as the Overall Winner of the 2024 Facility of the Year Awards (FOYA) for its IE2b facility based in Kinsale, Ireland. The winner was announced and formally ...